Abbott Laboratories Draws Bullish Targets As Legal Overhang Fades

Abbott Laboratories stocks have been trading up by 10.63 percent after strong earnings and upbeat medical device demand projections.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ABT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Are Watching

Baird started coverage on ABT with an Outperform rating and a $121 target, leaning on 6%-8% sales growth and new-product upside into 2027-2028.
Citi’s sum-of-the-parts work pegs ABT at $99–$104 versus roughly high-$80s, tying upside to easing headwinds and a fresh product cycle.
Evercore ISI trimmed its ABT target to $112 from $120 but kept an Outperform, citing solid MedTech and diagnostics demand into Q2.
The U.S. Department of Justice ended its years-long baby formula probe without criminal charges, shifting ABT’s exposure to a civil settlement.
A global ALZpath licensing deal positions Abbott Laboratories to develop a blood-based Alzheimer’s test on its Alinity systems.

Quick Financial Overview

ABT has been grinding higher on the chart, and the numbers underneath that move look like a mature but still growing MedTech story. Over the last few weeks, Abbott Laboratories has bounced from the high-$80s to close near $98.76, with several strong green sessions clustered around 2026/07/15–2026/07/16. That’s a notable squeeze from the recent $89 reference level used in Citi’s work.

On the intraday tape, ABT showed a classic trend day. After gapping up from the low-$90s, the stock pushed above $100 in the morning, then cooled off but held most of its gains, grinding in a tight $98.5–$100.5 band. For short-term traders, that kind of controlled pullback after a gap is usually a sign of real demand, not just a one-and-done spike.

More Breaking News

Under the hood, Abbott Laboratories prints about $44.3B in annual revenue with a gross margin above 56% and an EBIT margin near 19%. The latest quarter showed $11.16B in revenue and around $1.08B in net income, with diluted EPS of $0.61. Debt looks manageable with total-debt-to-equity around 0.65 and interest coverage above 22 times. ABT’s dividend yield near 2.8% adds a steady-income layer, which can support dips when the market gets choppy.

Why Traders Are Watching ABT Right Now

The story around ABT in mid-2026 is a mix of fresh analyst confidence, real-world catalysts, and a major legal cloud finally starting to clear. That combination is why active traders are back watching Abbott Laboratories’ tape more closely.

On the Street, the tone is firmly constructive. Baird just launched coverage on ABT with an Outperform rating and a $121 price target, well above where the stock has been trading. Their call leans on 6%-8% annual sales growth and low double-digit earnings growth through at least 2027-2028, driven by new products and potential synergies with Exact Sciences. For traders, that says one thing: institutions are positioning for a multi-year story, not a one-quarter bounce.

Citi backs that up with a sum-of-the-parts view that values Abbott Laboratories between $99 and $104, versus the high-$80s starting point they reference. They’re tying that upside to easing macro and product-cycle headwinds. In plain language, ABT has already worked through a lot of the noise, and the next chapter is about launches and execution.

At the same time, Evercore ISI trimmed its target from $120 to $112 but kept an Outperform rating, leaning on steady procedure volumes and capex trends in MedTech, life sciences tools, and diagnostics. That tweak tells traders the aggressive blue-sky numbers are getting tempered, but the fundamental demand picture for ABT remains solid.

On the catalyst side, Abbott Laboratories just signed a global licensing deal with ALZpath, using the pTau217 antibody to build a blood-based Alzheimer’s test on its widely installed Alinity ci-series systems. That is classic “platform leverage” — ABT isn’t building from scratch; it’s plugging a novel marker into machines that are already in labs worldwide. Traders should see this as a long runway story: not an instant EPS spike, but a pipeline move that can support the bullish price targets.

Finally, policy and legal headlines are shifting in ABT’s favor. The Centers for Medicare & Medicaid Services are proposing expanded TAVR coverage, and Abbott Laboratories is expected to benefit as a structural heart device player. Meanwhile, the U.S. Department of Justice has closed its years-long baby formula probe without criminal charges, heading instead toward a civil False Claims Act settlement. That removes the worst-case legal scenario, even though reputational and civil-cost overhangs remain.

Taken together, the tape, the targets, and the news all line up to keep ABT firmly on traders’ watchlists.

Conclusion

For traders, ABT right now is all about balancing a cleaner risk backdrop with a still-building growth story. The DOJ decision not to pursue criminal charges over Abbott Laboratories’ baby formula operations takes a big tail-risk off the table. A civil settlement on federal nutrition-program funds can still sting, but the binary fear of criminal headlines is gone. That helps explain why ABT has pushed from the high-$80s into the upper-$90s range as the news digested.

On the offense side, the Street’s stance remains notably bullish. Baird’s $121 call, Citi’s $99–$104 range, and Evercore’s $112 target all sit above the latest trading zone, even after Evercore’s trim. Each of these firms points to a similar core idea: Abbott Laboratories has a healthy pipeline, solid MedTech demand, and an innovation engine spanning diagnostics, cardiovascular devices, and nutrition. The ALZpath Alzheimer’s blood-test deal is a textbook example — a high-need area, tied into ABT’s existing Alinity footprint.

ABT is also working to repair and deepen trust in its nutrition franchise. The Similac “Love Without Measure” initiative aims straight at Gen Z and young millennial parents, leaning on influencers and judgment-free messaging. That’s brand work, not a day-trading catalyst, but over time it matters for volume and sentiment.

With Q2 2026 results scheduled for 2026/07/16, traders won’t have to wait long for fresh numbers. Earnings will test whether the upbeat talk on procedure volumes, diagnostics demand, and margin strength shows up in cash flow and EPS. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” In practical terms, that means treating the coming earnings print and any follow-through in price as the real signal, not just the optimistic chatter. In the words often used by Tim Sykes, the core mindset applies here too: “Trade the price action, not the hype — let the chart and the catalysts confirm your thesis.” For ABT, the next confirmation window is just around the corner.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!